BKBoris Karpov

Boris Karpov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Boris Karpov has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Internet-Delivered Cognitive Behavioral Therapy for Social Anxiety Disorder: Nationwide Retrospective Cohort Observational Study

    by Anna Paula Laizane, Ville Ritola, Tom H Rosenström, Suoma Eeva Saarni, Maya L Rutan, Boris Karpov, Satu Pihlaja, Jan-Henry Stenberg, Grigori Joffe

    Background: Internet-delivered cognitive behavioral therapies (iCBTs) can address the accessibility and affordability limitations of conventional therapy. Although iCBTs for social anxiety disorder (SAD) are efficacious, their effectiveness in routine care remains less well established. Helsinki University Hospital (HUS) provides a novel nationwide iCBT program for SAD. Objective: We aimed to assess whether this 7-session, flexible time-scheduled, therapist-supported HUS-iCBT for SAD, delivered by a specialized clinic, (1) is effective in routine care and (2) can enhance adherence, compared to previously published programs with ≥9 sessions. Methods: This retrospective, registry-based, observational cohort study used data from the HUS-iCBT register from 2019 to 2022. For treatment, the inclusion criteria were a diagnosis of SAD and possession of an email address and an official e-identification. Severe personality disorders, suicidal behavior, acute psychosis or mania, and disorders with cognitive decline were exclusion criteria. Altogether, 2360 physician-referred patients were accepted for therapy. For the study, we applied an additional criterion of ≥21 baseline score on the Social Phobia Inventory (SPIN, primary outcome) to verify the exclusion of subclinical conditions. Patients aged less than 18 years, with missing baseline information, who did not log-in, or reentered treatment were excluded. The remaining patients (n=1654) formed the modified intent-to-treat (mITT) population, provided they completed ≥1 on-therapy sessions. Secondary measures were Overall Anxiety Severity and Impairment Scale and Patient Health Questionnaire-9. Results: Linear mixed effects modeling revealed a large SPIN-measured effect size for mITT and completer populations (Cohen d =1.09, 95% CI 1.03‐1.16 and d =1.15, 95% CI 1.06‐1.23, respectively). Late and early dropouts also benefited from the treatment, with medium and small effect sizes, respectively ( d =0.41, 95% CI 0.32‐0.50 and d =0.72, 95% CI 0.58‐0.86). Reliable Change Index analysis showed improvement in 679 out of 1654 (41.1%, 95% CI 38.7‐43.5) patients in the mITT population and 516 out of 893 (57.8%, 95% CI 54.5‐61.0) patients in the completer population. Completers exhibited improvement also on secondary measures. Patients completed a mean of 5.74 (SD 1.99; 82%) of all 7 sessions (vs 59% and 68% in earlier programs with ≥9 sessions and 85.3% in one 6-session program). In the mITT population, 893 out of 1654 (54%, 95% CI 51.6‐56.4) patients were completers. Independent sample t test was applied for comparisons between groups. Missing data were analyzed with the Little MCAR (missing completely at random) test. Multiple testing was compensated using the Benjamini-Hochberg false discovery rate. Cronbach α was calculated at baseline and end point for outcomes. Conclusions: The innovative 7-session HUS-iCBT for SAD (vs ≥9 sessions in most previous programs) may improve adherence without compromising effectiveness. Task shifting from highly specialized to less specialized professionals may further improve cost-effectiveness, although formal health-economic evaluation is needed. These findings may inform the development of future iCBT programs for mental disorders.

  • Open Access

    The Overall Anxiety Severity and Impairment Scale as an Outcome Measure in Internet-Delivered Cognitive Behavioral Therapy for Anxiety Disorders: Observational Study

    by Boris Karpov, Jari Olavi Lipsanen, Ville Ritola, Tom Rosenström, Suoma Saarni, Satu Pihlaja, Jan-Henry Stenberg, Paula Laizane, Grigori Joffe

    Background: Internet-delivered cognitive behavioral therapy (iCBT) is effective in the treatment of anxiety disorders. iCBT clinical trials use relatively long and time-consuming disorder-specific rather than transdiagnostic anxiety measurements. Overall Anxiety Severity and Impairment Scale (OASIS) is a brief self-report scale that could offer a universal, easy-to-use anxiety measurement option in disorder-specific and transdiagnostic iCBT programs. Objective: We aimed to investigate relationships between OASIS and disorder-specific instruments in iCBT. We expected these relationships to be positive. Methods: We investigated patients in original nationwide iCBT programs for generalized anxiety disorder (GAD), obsessive-compulsive disorder, panic disorder, and social anxiety disorder, which were administered by Helsinki University Hospital, Finland. In each program, anxiety symptoms were measured using both disorder-specific scales (the 7-item Generalized Anxiety Disorder scale, Penn State Worry Questionnaire, revised Obsessive-Compulsive Inventory, Panic Disorder Severity Scale, and Social Phobia Inventory) and by OASIS. A general linear model for repeated measures (mixed models) and interaction analysis were used for investigating the changes and relationships in the mean scores of OASIS and disorder-specific scales from the first session to the last one. Results: The main effect of linear mixed models indicated a distinct positive association between OASIS and disorder-specific scale scores. Interaction analysis demonstrated relatively stable associations between OASIS and the revised Obsessive-Compulsive Inventory (F822.9=0.09; 95% CI 0.090-0.277; P=.32), and OASIS and the Panic Disorder Severity Scale (F596.6=–0.02; 95% CI –0.108 to –0.065; P=.63) from first the session to the last one, while the 7-item Generalized Anxiety Disorder scale (F4345.8=–0.06; 95% CI –0.109 to –0.017; P=.007), Penn State Worry Questionnaire (F4270.8=–0.52; 95% CI –0.620 to –0.437; P<.001), and Social Phobia Inventory (F862.1=–0.39; 95% CI –0.596 to –0.187; P<.001) interrelated with OASIS more strongly at the last session than at the first one. Conclusions: OASIS demonstrates clear and relatively stable associations with disorder-specific symptom measures. Thus, OASIS might serve as an outcome measurement instrument for disorder-specific and plausibly transdiagnostic iCBT programs for anxiety disorders in regular clinical practice.


  • Open Access

    The Overall Anxiety Severity and Impairment Scale as an Outcome Measure in Internet-Delivered Cognitive Behavioral Therapy for Anxiety Disorders: Observational Study (Preprint)

    by Boris Karpov, Jari Olavi Lipsanen, Ville Ritola, Tom Rosenström, Suoma Saarni, Satu Pihlaja, Jan-Henry Stenberg, Paula Laizane, Grigori Joffe

    BACKGROUND Internet-delivered cognitive behavioral therapy (iCBT) is effective in the treatment of anxiety disorders. iCBT clinical trials use relatively long and time-consuming disorder-specific rather than transdiagnostic anxiety measurements. Overall Anxiety Severity and Impairment Scale (OASIS) is a brief self-report scale that could offer a universal, easy-to-use anxiety measurement option in disorder-specific and transdiagnostic iCBT programs. OBJECTIVE We aimed to investigate relationships between OASIS and disorder-specific instruments in iCBT. We expected these relationships to be positive. METHODS We investigated patients in original nationwide iCBT programs for generalized anxiety disorder (GAD), obsessive-compulsive disorder, panic disorder, and social anxiety disorder, which were administered by Helsinki University Hospital, Finland. In each program, anxiety symptoms were measured using both disorder-specific scales (the 7-item Generalized Anxiety Disorder scale, Penn State Worry Questionnaire, revised Obsessive-Compulsive Inventory, Panic Disorder Severity Scale, and Social Phobia Inventory) and by OASIS. A general linear model for repeated measures (mixed models) and interaction analysis were used for investigating the changes and relationships in the mean scores of OASIS and disorder-specific scales from the first session to the last one. RESULTS The main effect of linear mixed models indicated a distinct positive association between OASIS and disorder-specific scale scores. Interaction analysis demonstrated relatively stable associations between OASIS and the revised Obsessive-Compulsive Inventory (F822.9=0.09; 95% CI 0.090-0.277; P=.32), and OASIS and the Panic Disorder Severity Scale (F596.6=–0.02; 95% CI –0.108 to –0.065; P=.63) from first the session to the last one, while the 7-item Generalized Anxiety Disorder scale (F4345.8=–0.06; 95% CI –0.109 to –0.017; P=.007), Penn State Worry Questionnaire (F4270.8=–0.52; 95% CI –0.620 to –0.437; P<.001), and Social Phobia Inventory (F862.1=–0.39; 95% CI –0.596 to –0.187; P<.001) interrelated with OASIS more strongly at the last session than at the first one. CONCLUSIONS OASIS demonstrates clear and relatively stable associations with disorder-specific symptom measures. Thus, OASIS might serve as an outcome measurement instrument for disorder-specific and plausibly transdiagnostic iCBT programs for anxiety disorders in regular clinical practice.

  • Open Access

    Psychotic Symptoms and Malignant Neuroleptic Syndrome in Williams Syndrome: A Case Report

    by Boris Karpov, Maria Muhonen, Tuula Kieseppä

    Background: Somatic and mental comorbidities are characteristic of individuals with Williams syndrome. The psychiatric profile of these patients mainly comprises affective disorders, while psychotic symptoms are rare.Methods: We present a case report of psychosis and malignant neuroleptic syndrome in a patient with Williams syndrome. We also conduct a review of recent works on the topic.Case Presentation: A 38-year-old Caucasian male with Williams syndrome presented with somatic delusions, previously experiencing severe anxiety and concerns about a headache. The patient was prescribed olanzapine, which did not, however, have any effect on the delusions. After switching to lurasidone, the patient presented with malignant neuroleptic syndrome (muscle rigidity, tremor, urinary retention, fluctuating level of consciousness). He was hospitalized and the antipsychotic medication was discontinued. After somatic recovery, the patient did not experience severe anxiety and the somatic delusions diminished notably. The patient was discharged from the hospital in a stable physical condition, albeit still with transient worries about his health condition.Conclusions: We present a case of the coincidence of Williams syndrome and psychosis. We hypothesize on the possible pathological relationships between the onset of the psychosis and severe anxiety in an individual with Williams syndrome. This case report duly contributes to the limited literature on psychiatric comorbidity in Williams syndrome.


  • Cognitive functioning and cannabis use in first-episode psychosis

    by Boris Karpov, Maija Lindgren, Tuula Kieseppä, Asko Wegelius, Jaana Suvisaari

    Cannabis use is common in people with psychotic disorders. However, the effect of cannabis on cognition in psychosis remains unclear. Our study investigates relationships between the history of can...


  • Open Access

    Anxiety symptoms in first‐episode psychosis

    by Boris Karpov, Tuula Kieseppä, Maija Lindgren, Asko Wegelius, Jaana Suvisaari

    Aim: Anxiety disorders and symptoms are common in people with psychotic disorders, having a negative impact on clinical status, function level and overall prognosis. However, research on the significance of anxiety in predicting remission and long‐term functioning in first‐episode psychosis (FEP) is still scarce. This study investigated the effects of anxiety and obsessive‐compulsive symptoms (OCS) on clinical and functional improvement in individuals with FEP.Methods: FEP patients (N = 97) aged 18‐40 years were recruited from the University Hospital District of Helsinki and the City of Helsinki. Psychotic and anxiety symptoms were measured using the Brief Psychiatric Rating Scale. Obsessive‐compulsive symptoms were assessed using the Obsessive‐Compulsive Inventory (OCI‐R), and functioning was evaluated using the Social and Occupational Functioning Assessment Scale (SOFAS). Follow‐up measurements were performed at 2 and 12 months. We specifically studied whether anxiety and obsessive‐compulsive symptoms at the 2‐month follow‐up assessment, at a time when the initial treatment response had been achieved, would predict outcomes at 12 months.Results: Symptoms of anxiety and OCS correlated moderately with each other and psychotic symptoms, but at the 12‐month follow‐up, OCS no longer correlated significantly with psychotic and anxiety symptoms. When the level of psychotic symptoms was adjusted for, more severe OCS at the 2‐month follow‐up was associated with a lower rate of remission at 12 months, whereas a higher level of anxiety symptoms at 2 months was associated with better functioning at 12 months.Conclusions: OCS may be predictive of poorer clinical outcomes, whereas anxiety symptoms may predict better functional outcomes.


  • Self-reported treatment adherence among psychiatric in- and outpatients

    by Boris Karpov, Grigori Joffe, Kari Aaltonen, Jorma Oksanen, Kirsi Suominen, Tarja Melartin, Ilya Baryshnikov, Maaria Koivisto, Martti Heikkinen, Erkki T. Isometsä

    Background: Poor adherence to psychiatric treatment is a common clinical problem, leading to unfavourable treatment outcome and increased healthcare costs. Aim: The aim of this study was to investigate the self-reported adherence and attitudes to outpatient visits and pharmacotherapy in specialized care psychiatric patients. Methods: Within the Helsinki University Psychiatric Consortium (HUPC) pilot study, in- and outpatients with schizophrenia or schizoaffective disorder (SSA, n = 113), bipolar disorder (BD, n = 99), or depressive disorder (DD, n = 188) were surveyed about their adherence and attitudes towards outpatient visits and pharmacotherapy. Correlates of self-reported adherence to outpatient and drug treatment were investigated using regression analysis. Results: The majority (78.5%) of patients reported having attended outpatient visits regularly or only partly irregularly. Most patients (79.2%) also reported regular use of pharmacotherapy. Self-reported non-adherence to preceding outpatient visits was consistently and significantly more common among inpatients than outpatients across all diagnostic groups (p < .001). Across all groups, hospital setting was the strongest independent correlate of poor adherence to outpatient visits (SSA β = –2.418, BD β = –3.417, DD β = –2.766; p < .001 in all). Another independent correlate of non-adherence was substance use disorder (SSA β = –1.555, p = .001; BD β = –1.535, p = .006; DD β = –2.258, p < .000). No other socio-demographic or clinical factor was significantly associated with poor adherence in multivariate regression models. Conclusions: Irrespective of diagnosis, self-reported adherence to outpatient care among patients with schizophrenia or schizoaffective disorder, bipolar disorder, and depression is associated strongly with two factors: hospital setting and substance use disorders. Thus, detection of adherence problems among former inpatients and recognition and treatment of substance misuse are important to ensure proper outpatient care.


  • Self-reported psychosis-like experiences in patients with mood disorders

    by I. Baryshnikov, K. Aaltonen, M. Koivisto, T. Melartin, P. Näätänen, K. Suominen, B. Karpov, M. Heikkinen, J. Oksanen, T. Paunio, et al.

    Background: Self-reported psychosis-like experiences (PEs) may be common in patients with mood disorders, but their clinical correlates are not well known. We investigated their prevalence and relationships with self-reported symptoms of depression, mania, anxiety, borderline (BPD) and schizotypal (SPD) personality disorders among psychiatric patients with mood disorders. Methods: The Community Assessment of Psychic Experiences (CAPE-42), Mood Disorder Questionnaire (MDQ), McLean Screening Instrument (MSI), The Beck Depressive Inventory (BDI), Overall Anxiety Severity and Impairment Scale (OASIS) and Schizotypal Personality Questionnaire-Brief form (SPQ-B) were filled in by patients with mood disorders (n = 282) from specialized care. Correlation coefficients between total scores and individual items of CAPE-42 and BDI, SPQ-B, MSI and MDQ were estimated. Hierarchical multivariate regression analysis was conducted to examine factors influencing the frequency of self-reported PE. Results: PEs are common in patients with mood disorders. The "frequency of positive symptoms" score of CAPE-42 correlated strongly with total score of SPQ-B (rho = 0.63; P < 0.001) and moderately with total scores of BDI, MDQ OASIS and MSI (rho varied from 0.37 to 0.56; P < 0.001). Individual items of CAPE-42 correlated moderately with specific items of BDI, MDQ SPQ-B and MSI (r(phi) varied from 0.2 to 0.5; P < 0.001). Symptoms of anxiety, mania or hypomania and BPD were significant predictors of the "frequency of positive symptoms" score of CAPE-42. Conclusions: Several, state- and trait-related factors may underlie self-reported PEs among mood disorder patients. These include cognitive-perceptual distortions of SPD; distrustfulness, identity disturbance, dissociative and affective symptoms of BPD; and cognitive biases related to depressive or manic symptoms. (C) 2016 Elsevier Masson SAS. All rights reserved.


  • Psychoactive substance use in specialized psychiatric care patients

    by Boris Karpov, Grigori Joffe, Kari Aaltonen, Jaana Suvisaari, Ilya Baryshnikov, Maaria Koivisto, Tarja Melartin, Kirsi Suominen, Petri Näätänen, Martti Heikkinen, et al.

    Objective: Life expectancy of psychiatric patients is markedly shorter compared to the general population, likely partly due to smoking or misuse of other substances. We investigated prevalence and correlates of substance use among psychiatric patients. Methods: Within the Helsinki University Psychiatric Consortium Study, data were collected on substance use (alcohol, smoking, and illicit drugs) among patients with schizophrenia or schizoaffective disorder (n = 113), bipolar (n = 99), or depressive disorder (n = 188). Clinical diagnoses of substance use were recorded, and information on smoking, hazardous alcohol use, or misuse of other substances was obtained using questionnaires. Results: One-fourth (27.7%) of the patients had clinical diagnoses of substance use disorders. In addition, in the Alcohol Use Disorders Identification Test, 43.1% had hazardous alcohol use and 38.4% were daily smokers. All substance use was more common in men than in women. Bipolar patients had the highest prevalence of alcohol use disorders and hazardous use, whereas those with schizophrenia or schizoaffective disorder were more often daily smokers. In regression analyses, self-reported alcohol consumption was associated with symptoms of anxiety and borderline personality disorder and low conscientiousness. No associations emerged for smoking. Conclusions: The vast majority of psychiatric care patients have a diagnosed substance use disorder, hazardous alcohol use, or smoke daily, males more often than females. Bipolar patients have the highest rates of alcohol misuse, schizophrenia or schizoaffective disorder patients of smoking. Alcohol use may associate with symptoms of anxiety, borderline personality disorder, and low conscientiousness. Preventive and treatment efforts specifically targeted at harmful substance use among psychiatric patients are necessary.


  • Self-reported symptoms of schizotypal and borderline personality disorder in patients with mood disorders

    by I. Baryshnikov, J. Suvisaari, K. Aaltonen, M. Koivisto, P. Näätänen, B. Karpov, T. Melartin, J. Oksanen, K. Suominen, M. Heikkinen, et al.

    BackgroundDistinguishing between symptoms of schizotypal (SPD) and borderline personality disorders (BPD) is often difficult due to their partial overlap and frequent co-occurrence. We investigated correlations in self-reported symptoms of SPD and BPD in questionnaires at the levels of both total scores and individual items, examining overlapping dimensions.MethodsTwo questionnaires, the McLean Screening Instrument (MSI) for BPD and the Schizotypal Personality Questionnaire Brief (SPQ-B) for SPD, were filled in by patients with mood disorders (n = 282) from specialized psychiatric care in a study of the Helsinki University Psychiatric Consortium. Correlation coefficients between total scores and individual items of the MSI and SPQ-B were estimated. Multivariate regression analysis (MRA) was conducted to examine the relationships between SPQ-B and MSI.ResultsThe Spearman's correlation between total scores of the MSI and SPQ-B was strong (rho = 0.616, P < 0.005). Items of MSI reflecting disrupted relatedness and affective dysregulation correlated moderately (rφ varied between 0.2 and 0.4, P < 0.005) with items of SPQ. Items of MSI reflecting behavioural dysregulation correlated only weakly with items of SPQ. In MRA, depressive symptoms, sex and MSI were significant predictors of SPQ-B score, whereas symptoms of anxiety, age and SPQ-B were significant predictors of MSI score.ConclusionsItems reflecting cognitive-perceptual distortions and affective symptoms of BPD appear to overlap with disorganized and cognitive-perceptual symptoms of SPD. Symptoms of depression may aggravate self-reported features of SPQ-B, and symptoms of anxiety features of MSI. Symptoms of behavioural dysregulation of BPD and interpersonal deficits of SPQ appear to be non-overlapping.